Why the study?
Do PPAR-gamma ligands reduce the severity of experimental autoimmune myocarditis in Lewis rats?
Do PPAR-gamma ligands reduce the severity of experimental autoimmune myocarditis in Lewis rats?
PPAR-gamma ligands ameliorate experimental autoimmune myocarditis in rats by inhibiting self-sensitive T cells, suggesting a potential therapeutic role in human inflammatory heart diseases.
Should not change myocarditis management; leaves open translation of PPAR-gamma ligands to human inflammatory heart disease.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: